Evrofarma Statistics
Total Valuation
Evrofarma has a market cap or net worth of EUR 18.87 million. The enterprise value is 35.54 million.
Market Cap | 18.87M |
Enterprise Value | 35.54M |
Important Dates
The next estimated earnings date is Monday, December 23, 2024.
Earnings Date | Dec 23, 2024 |
Ex-Dividend Date | Sep 12, 2024 |
Share Statistics
Evrofarma has 13.67 million shares outstanding. The number of shares has increased by 0.05% in one year.
Current Share Class | n/a |
Shares Outstanding | 13.67M |
Shares Change (YoY) | +0.05% |
Shares Change (QoQ) | -0.06% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
The trailing PE ratio is 8.63.
PE Ratio | 8.63 |
Forward PE | n/a |
PS Ratio | 0.40 |
PB Ratio | 1.07 |
P/TBV Ratio | n/a |
P/FCF Ratio | 7.70 |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.86, with an EV/FCF ratio of 14.50.
EV / Earnings | 16.25 |
EV / Sales | 0.76 |
EV / EBITDA | 6.86 |
EV / EBIT | 10.30 |
EV / FCF | 14.50 |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.97.
Current Ratio | 1.38 |
Quick Ratio | 0.73 |
Debt / Equity | 0.97 |
Debt / EBITDA | 3.33 |
Debt / FCF | 6.99 |
Interest Coverage | 2.61 |
Financial Efficiency
Return on equity (ROE) is 13.23% and return on invested capital (ROIC) is 5.83%.
Return on Equity (ROE) | 13.23% |
Return on Assets (ROA) | 4.12% |
Return on Capital (ROIC) | 5.83% |
Revenue Per Employee | 282,193 |
Profits Per Employee | 13,175 |
Employee Count | 156 |
Asset Turnover | 0.90 |
Inventory Turnover | 4.37 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +42.93% in the last 52 weeks. The beta is 1.03, so Evrofarma's price volatility has been similar to the market average.
Beta (5Y) | 1.03 |
52-Week Price Change | +42.93% |
50-Day Moving Average | 1.50 |
200-Day Moving Average | 1.56 |
Relative Strength Index (RSI) | 45.99 |
Average Volume (20 Days) | 4,105 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Evrofarma had revenue of EUR 46.84 million and earned 2.19 million in profits. Earnings per share was 0.16.
Revenue | 46.84M |
Gross Profit | 7.06M |
Operating Income | 3.42M |
Pretax Income | 2.76M |
Net Income | 2.19M |
EBITDA | 5.10M |
EBIT | 3.42M |
Earnings Per Share (EPS) | 0.16 |
Balance Sheet
The company has 470,000 in cash and 17.14 million in debt, giving a net cash position of -16.67 million or -1.22 per share.
Cash & Cash Equivalents | 470,000 |
Total Debt | 17.14M |
Net Cash | -16.67M |
Net Cash Per Share | -1.22 |
Equity (Book Value) | 17.63M |
Book Value Per Share | 1.29 |
Working Capital | 5.20M |
Cash Flow
In the last 12 months, operating cash flow was 4.74 million and capital expenditures -2.29 million, giving a free cash flow of 2.45 million.
Operating Cash Flow | 4.74M |
Capital Expenditures | -2.29M |
Free Cash Flow | 2.45M |
FCF Per Share | 0.18 |
Margins
Gross margin is 15.08%, with operating and profit margins of 7.29% and 4.67%.
Gross Margin | 15.08% |
Operating Margin | 7.29% |
Pretax Margin | 5.89% |
Profit Margin | 4.67% |
EBITDA Margin | 10.90% |
EBIT Margin | 7.29% |
FCF Margin | 5.23% |
Dividends & Yields
This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 3.53%.
Dividend Per Share | 0.05 |
Dividend Yield | 3.53% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.05% |
Shareholder Yield | 3.49% |
Earnings Yield | 11.59% |
FCF Yield | 12.99% |
Stock Splits
The last stock split was on July 26, 2001. It was a forward split with a ratio of 2.
Last Split Date | Jul 26, 2001 |
Split Type | Forward |
Split Ratio | 2 |
Scores
Evrofarma has an Altman Z-Score of 1.96. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.96 |
Piotroski F-Score | n/a |